Vascular Access for Hemodialysis Patients: New Data Should Guide Decision Making

Area of Science:

• Nephrology
• Vascular Surgery
• Dialysis Access

Background:

• The 2006 Kidney Disease Outcomes Quality Initiative (KDOQI) vascular access guidelines are widely influential.
• Contemporary United States hemodialysis populations have evolved since 2006.
• Critical re-evaluation of guideline assumptions is necessary for current clinical practice.

Purpose of the Study:

• To critically examine the assumptions and recommendations of the 2006 KDOQI vascular access guidelines.
• To assess the contemporary relevance of these guidelines to the United States hemodialysis population.
• To present evidence challenging established beliefs regarding vascular access types and outcomes.

Main Methods:

• Commentary and critical analysis of existing literature and guideline recommendations.
• Review of intent-to-treat analyses comparing arteriovenous fistulas (AVFs) and arteriovenous grafts (AVGs).
• Examination of data on infection rates, access management costs, maturation times, and mortality associated with different vascular access types.

Main Results:

• Intent-to-treat analyses show equivalent secondary survival for AVFs and AVGs, contrary to guideline preference for AVFs.
• Catheter-related bloodstream infections before AVF maturation can offset lower AVF infection rates.
• Assisted maturation of AVFs is linked to inferior secondary patency compared to AVGs.
• Overall access management costs may be higher for AVFs in certain patient cohorts.
• Upper arm AVFs demonstrate superior maturation compared to forearm AVFs.
• Suboptimal arterial vasodilation may contribute to AVF nonmaturation alongside stenosis.
• Central venous catheter (CVC) use appears to be a surrogate marker for patient acuity rather than a direct cause of mortality.

Conclusions:

• Several key recommendations in the 2006 KDOQI vascular access guidelines may not align with current evidence and the realities of the US hemodialysis population.
• The preference for AVFs over AVGs requires re-evaluation based on comparable survival and considerations of primary failure and infection rates.
• The role and impact of CVCs on mortality warrant further investigation, with current data suggesting a surrogate relationship.
• Future guidelines should incorporate updated evidence on AVF maturation, access management costs, and the multifactorial nature of access failure.